Elusive proatherothrombotic role of Lp(a): A new direction?

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 5, 2006, Pages 971-972

  Hoover Plow, Jane ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; COLLAGEN; FIBRIN; GROWTH FACTOR; LIPOPROTEIN A; PLASMINOGEN; SCLEROPROTEIN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOT; BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; CELL MIGRATION; CORONARY ARTERY DISEASE; FIBRIN CLOT; FIBRINOLYSIS; HEART INFARCTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NOTE; PATHOPHYSIOLOGY; PERMEABILITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RISK FACTOR; THROMBOGENESIS; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ATHEROSCLEROSIS; HUMANS; LIPOPROTEIN(A); MICE; RABBITS; THROMBOSIS;

EID: 33645650322     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01946.x     Document Type: Note

References (10)

1. Berg K. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand 1963; 59: 369-82
2. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease -meta-analysis of prospective studies. Circulation 2000; 102: 1082-5.
3. von Depka M, Nowak-Gottl U, Eisert R, Dieterich C, Barthels M, Scharrer I, Ganser A, Ehrenforth S. Increased lipoprotein(a) levels as an independent risk factor for venous thromboembolism. Blood 2000; 96: 3364-8.
4. Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nature Med 1995; 1: 256-9
5. Biemond BJ, Friederich PW, Koschinsky ML, Levi M, Sangrar W, Xia J, Buller HR, ten Cate JW. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation 1997; 96: 1612-5.
6. Sha J, McCullough B, Hart E, Nassir F, Davidson NO, Hoover-Plow J. Apo(a) promotes thrombosis in a vascular injury model by a mechanism independent of plasminogen. J Thromb Haemost 2005; 3: 2281-9.
7. Undas A, Stepien E, Tracz W, Szczeklik A. Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost 2006; 4: 973-5
8. Mills JD, Ariens RA, Mansfield MW, Grant PJ. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-42.
9. Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: Dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-61.
10. Angles-Cano E, de la Pena DA, Loyau S. Inhibition of fibrinolysis by lipoprotein(a). Ann NY Acad Sci 2001; 936: 261-75